Elestrin™ is a new gel formulation of estradiol that benefits from the technological advantages of transdermal administration. By virtue of its sustained release, Elestrin may be applied once daily.

It will be a relief for women dealing with years of shortages of oestrogen patches.

ANI’s Estradiol Gel, 0.06% is the generic version of the reference listed drug (RLD) EstroGel ® Gel, 0.06%. "With the FDA approval and commercialization of Estradiol Gel, 0.06%, we are pleased ...

ANI Pharmaceuticals, Inc., a diversified biopharmaceutical company, announced that following final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application ...

ANI Pharmaceuticals (NASDAQ:ANIP) announced that following final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application, the company launched Estradiol Gel, 0.06% ...

Elestrin™ (transdermal estradiol gel) is a new gel formulation of bioidentical estradiol developed by BioSante Pharmaceuticals, Inc. (IL, USA). In Elestrin, estradiol is carried in a patent ...

ANI Pharmaceuticals (ANIP) announced that following final approval from the U.S. FDA for its Abbreviated New Drug Application, the company ...

"With the FDA approval and commercialization of Estradiol Gel, 0.06%, we are pleased to bring another limited-competition product to market and ensure that customers and patients in need have ready ...